Spots Global Cancer Trial Database for Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Official Title: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Study ID: NCT02298283
Conditions
Study Description
Brief Summary: This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).
Detailed Description: This study aims to evaluate the progression free survival after treatment for patient with stage I/II supradiaphragmatic HL patient and PET positive after 2 courses of ABVD. The treatment consist of 3 phases : * induction treatment with 2 cycles every 3 weeks of bleomycin, etoposide, Adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone (BEACOPP) escalated * radiotherapy 30 Gy starting 3 to 4 weeks after last day of second course of BEACOPP-escalated * consolidation treatment with 8 cycles every 21 days of brentuximab vedotin
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CH Victor Dupouy, Argenteuil, , France
Polyclinique Bordeaux Nord, Bordeaux, , France
Centre François Baclesse, Caen, , France
CH de Chambéry, Chambéry, , France
CH Sud Francilien, Corbeil-Essonnes, , France
Hôpital Henri Mondor, Creteil, , France
CHU de Dijon - Hôpital le Bocage, Dijon, , France
Hôpital André Mignot, Le Chesnay, , France
Clinique Victor Hugo, Le Mans, , France
CHRU Lille - Hôpital Claude Huriez, Lille, , France
CHU de Limoges, Limoges, , France
Centre Léon Bérard, Lyon, , France
Institut Paoli Calmette, Marseille, , France
Hôpital de la Conception, Marseille, , France
CHU Montpellier - Saint ELOI, Montpellier, , France
CHU de Nantes, Nantes, , France
Hôpital Saint Louis, Paris cedex 10, , France
Hôpital Cochin, Paris, , France
Hôpital de la Pitié Salpétrière, Paris, , France
CH Perpignan, Perpignan, , France
Hôpital Haut Lévêque, Pessac, , France
CHU Lyon Sud, Pierre Bénite Cedex, , France
CHU Robert Debre, Reims, , France
CHU Pontchaillou, Rennes, , France
Centre Henri Becquerel, Rouen, , France
CHU de Strasbourg, Strasbourg, , France
I.U.C.T Oncopole, Toulouse, , France
CHU Bretonneau, Tours, , France
CHU de Brabois, Vandœuvre-lès-Nancy, , France
Gustave Roussy Cancer Campus, Villejuif, , France
Contact Details
Name: Pauline BRICE, MD
Affiliation: Lymphoma Study Association
Role: PRINCIPAL_INVESTIGATOR
Name: Thomas GASTINNE, MD
Affiliation: Lymphoma Study Association
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
